Introduction {#s1}
============

Bipolar disorder (BD) has been described since the times of Hippocrates and Areteus, but recently the subtypes BD-I and BD-II were proposed with a combined prevalence rate of up to 2.4% ([@CIT0195]). The treatment of BD is probably the most challenging of all mental disorders with the unique characteristic that each phase needs a different treatment approach ([@CIT0332]).

Such complex mental disorders are those that are expected to benefit more by the development of treatment guidelines, which during the last few decades are becoming an ever more important part of medical reality. This is especially since the translation of research findings to everyday clinical practice is becoming increasingly difficult with the accumulation of complex and often conflicting research findings, which are thereafter also included in meta-analysis. Guidelines aim to assist clinicians but also policymakers to arrive at decisions concerning the treatment and care of patients. They set the standard of care and training for health professionals, and they identify priority areas for further research since they are based primarily on the available evidence, but also, in areas where evidence is not available, on expert opinion.

The literature suggests that depression rather than mania is the most challenging phase ([@CIT0178]). If subsyndromal, the presence of residual symptoms impose a greater risk of relapse ([@CIT0142]), greater disability, and poorer overall outcome ([@CIT0312], [@CIT0313], [@CIT0318]). Therefore, full remission and recovery should be the ultimate treatment goal. A significant proportion of patients, however, do not fully respond to treatment, and their long-term course is characterized by frequent relapses and residual symptoms, causing significant disability and functional impairment ([@CIT0077]).

To fulfil this need for expert translation of research findings into clinical practice and for the benefit of patients, the International College of Neuropsychopharmacology (CINP) launched an effort to critically appraise the literature and provide guidance to clinicians in the form of a treatment algorithm and guidelines as precise as the data allow. It is hoped that they will help the clinician to follow the state-of-the-art evidence, thus enabling their clinical practice to be based on informed decision-making process. They have been commissioned by the CINP, and the working group consisted of experts with extensive research and clinical experience in the field of BD. There was no funding from any source for the development of the guidelines and the activities of the working group.

All the members of the working group were psychiatrists who are in active clinical practice and were selected according to their expertise with the aim to cover a multitude of different cultures. All of them were involved in research and other academic activities, and therefore it is possible that through such activities some contributors have received income related to medicines discussed in this guideline. All conflicts of interest are mentioned at the end of this paper, which is the introductory paper to the CINP BD guidelines. It should also be noted that some drugs recommended in the guideline may not be available in all countries, and labeling and dosing might vary.

This project has already developed treatment algorithms and guidelines for BD (Fountoulakis et al., 2017a, 2017b, 2017c, 2017d), and the next step would be to search for data in the area of BD resistant to treatment.

Aim of the Current Study {#s2}
========================

The aim of the current study was to perform a PRISMA systematic review of the literature concerning (1) the definition of treatment resistance in BD, (2) its clinical and (3) neurobiological correlates, and (4) the evidence-based treatment options for treatment-resistant BD.

Materials and Methods {#s3}
=====================

The PRISMA method ([@CIT0130]; [@CIT0161]; [@CIT0201]) was followed in the search of the literature. We searched MEDLINE to April 22, 2018 with the combination of keywords "refractory" or "refractoriness" or "resistant" with "mania," "manic," "bipolar," "manic-depressive," or "manic-depression." The PRISMA flowchart is shown in [Figure 1](#F1){ref-type="fig"}.

![The PRISMA flowchart.](pyz064f0001){#F1}

The following inclusion criteria were utilized:

1.  Papers in English language

2.  Papers reporting specifically on BD, not on affective disorders in general. If the paper concerned affective disorders in general then there should be a specific elaboration on BD.

3.  Concerning the definition of treatment resistance in BD: any paper that included a description or any kind of definition.

4.  Papers considering resistant bipolar depression on the basis of failure of antidepressant treatment were not included. An exception was made for those specific antidepressants with a proven efficacy in the treatment of BD according to the CINP Bipolar Disorder Treatment Guidelines.

5.  For clinical and neurobiological correlates we considered only papers with original data.

6.  Concerning treatment options, all papers with original data, systematic reviews, and meta-analyses as well as post-hoc analyses were included.

7.  Case reports and case series (including retrospective chart reviews) were not included (either referenced as such or according to the author's judgement).

Relevant review papers were scanned to locate additional studies ([@CIT0237]; [@CIT0133]; [@CIT0367]; [@CIT0124]). The data concerning the treatment of resistant BD were ranked according to the method previously developed by the authors ([@CIT0370]) and shown in [Table 1](#T1){ref-type="table"}.

###### 

Summary of the method for grading data and recommendation on the basis of both efficacy and safety/tolerability

  Grading on basis of efficacy                                                      
  --------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Level 1                                                                           Good research-based evidence, supported by at least 2 placebo controlled studies of sufficient magnitude and good quality. In case of the presence of negative RCTs, positive RCTs should outnumber negative ones
  Level 2                                                                           Fair research-based evidence, from 1 randomized, double-blind placebo controlled trial Also in case 1 or more trials exist, however, they fail to fulfil all the criteria above (e.g., very small sample size or no placebo control) as well as in case of positive meta-analysis alone
  Level 3                                                                           Some evidence from comparative studies without placebo arm or from post-hoc analyses
  Level 4                                                                           Inconclusive data or poor-quality RCTs
  Level 5                                                                           Negative data
  Grading on the basis of safety and tolerability                                   
  Level 1                                                                           Very good tolerability, few side effects that are not enduring, do not cause significant distress, and are not life-threatening and do not compromise the overall somatic health of patient
  Level 2                                                                           Moderate tolerability, many side effects that could be enduring, and cause significant distress but are not life-threatening, although they could compromise the overall somatic health of the patient Agents with very good overall tolerability but with rare life-threatening adverse events, could be classified here only if the lethality risk can be essentially considered to be negligible with application of procedures and protocols (e.g., laboratory testing, titration schedules, etc.)
  Level 3                                                                           Poor tolerability, many side effects that are enduring, cause significant distress, compromise the overall somatic health of patient, or are life-threatening Agents with moderate overall tolerability and rare, life-threatening adverse events should be classified here even in case the lethality risk can be essentially considered to be negligible with the application of procedures and protocols (e.g., laboratory testing, titration schedules, etc.)
  Recommendations for treatment (combination of efficacy and safety/tolerability)   
  Level 1                                                                           Level 1 or 2 for efficacy and 1 for safety/tolerability
  Level 2                                                                           Level 1 or 2 for efficacy and 2 for safety/tolerability
  Level 3                                                                           Level 3 for efficacy and 1 or 2 for safety/tolerability
  Level 4                                                                           Level 4 for efficacy or 3 for safety/tolerability
  Level 5                                                                           Level 5 for efficacy (not recommended)

Abbreviation: RCT, randomized controlled trial.

Results {#s4}
=======

Definitions of Treatment Resistance in BD (n = 37) {#s5}
--------------------------------------------------

There are several approaches to define "response," "remission," "recovery," "relapse," and "recurrence" in mental disorders. Although these definitions have been used in observational studies ([@CIT0312], [@CIT0313], [@CIT0315], [@CIT0316]), a common starting point is that these definitions apply to patients who received treatment with an adequate dosage of an effective treatment modality for a sufficient duration of time. Patients unable to tolerate such an adequate therapeutic trial for any reason as well as noncompliant patients are usually considered as "pseudorefractory" ([Table 2](#T2){ref-type="table"}).

###### 

Issues to be addressed in order to label a patient as "resistant"

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1. Correct diagnosis
  2. Disorder not secondary to an organic disorder
  3. Poor response to treatment not due to somatic or mental comorbidity
  4. Poor response to treatment not due to a somatic condition that might not constitute a disorder by itself (e.g., genetic factors, smoking, alcohol use, gender, race, etc.)
  5. Failure of therapy not due to nontolerability
  6. Patient complies with recommended treatment and poor response not a consequence of lack of adherence
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Some authors suggest that the basis is an inadequate response to a therapeutic trial of lithium or an inability to tolerate lithium's side effects ([@CIT0014]; [@CIT0010]; [@CIT0152]; [@CIT0021]; [@CIT0238]; [@CIT0277]; [@CIT0184]; [@CIT0003]; [@CIT0042]; [@CIT0122]). Others consider a different definition on the basis of nonresponse to carbamazepine ([@CIT0152]; [@CIT0020]; [@CIT0277]) or valproate ([@CIT0042]), and their definition of failure also included intolerance. A more restrictive definition of treatment resistance demands failure to respond to at least 2 agents ([@CIT0182]; [@CIT0148]; [@CIT0041]), while other authors defined wider degrees of treatment nonresponse (tertiary resistance) ([@CIT0331]; [@CIT0053]; [@CIT0122]; [@CIT0300]; [@CIT0270]).

The first comprehensive attempt defined treatment-resistant mania as mania without remission despite adequate therapy with at least 2 antimanic agents (lithium, antipsychotic, anticonvulsant, etc.) for at least 6 weeks on each agent in the absence of antidepressants or other mood-elevating agents ([@CIT0264]). For resistant bipolar depression, an extrapolation of the definition for unipolar to bipolar depression would be appropriate, which means no remission despite 2 adequate trials of standard antidepressant agents (6 weeks each), with or without augmentation strategies ([@CIT0264]). However, this definition is currently not supported by the data in a fundamental way since antidepressants are not considered to be efficacious in the treatment of bipolar depression, although they are among the most commonly used agents ([@CIT0011]; [@CIT0032]; [@CIT0144]). Treatment-resistant mood cycling (resistance in the long term) was defined as continued cycling despite maximal tolerated lithium in combination with valproate or carbamazepine for a period of 3 times the average cycle length, or 6 months, whichever is longer, in the absence of antidepressants or other cycle-promoting agents ([@CIT0264]). This definition is not in accord with the data concerning the efficacious treatment of these conditions ([@CIT0264]).

The only attempt to grade treatment resistance of a stratified response/refractoriness graduation suggested the clustering of resistant cases into 3 groups: (1) primary resistance, that is, inadequate response to a therapeutic trial of lithium (\>0.7 mmol/L), valproate, or carbamazepine; (2) secondary resistance, that is, inadequate response to sequential therapeutic trials of 2 mood stabilizers or an antipsychotic and a mood stabilizer; and (3) tertiary resistance, that is, inadequate response to sequential therapeutic trials of 3 agents: any antipsychotics, 2 mood stabilizers and an antipsychotic, 2 antipsychotics and a mood stabilizer, or 3 mood stabilizers ([@CIT0140]).

Another definition was based on the assumption that lithium at serum levels of 0.8 mmol/L or greater for at least 6 weeks should be the first line of treatment for bipolar depression if a patient is not already on a mood stabilizer and if lithium fails, the addition of lamotrigine, carbamazepine, valproate, antidepressants (not tricyclic antidepressants), or an atypical antipsychotic such as olanzapine might be a reasonable second-line options ([@CIT0348]; [@CIT0317]; [@CIT0310]). This is in partial agreement with the data currently available. In the STEP-BD study, treatment-resistant depression was defined as no response to treatment after 12 weeks of treatment or a well-documented failure to respond to at least 2 trials of antidepressants or an antidepressant and a mood stabilizer ([@CIT0211]).

A more sophisticated 4-level system for the staging of resistance from resistance to a single agent to resistant to 3 agents plus neurostimulation has been proposed, but its clinical relevance is unclear since it puts the emphasis on the number of treatment options used but ignores other important details, including duration. It includes the following stages: Stage I: failed monotherapy trial of lithium, anticonvulsant, or atypical antipsychotic of adequate dose and for adequate duration (FDA-approved treatment based on mood episode); Stage II: Stage I plus failed trial of combination of 2 medications, lithium, or anticonvulsant and atypical antipsychotic; Stage III: Stage II plus failed trial of several different evidence-based adjunctive pharmacological compounds; and Stage IV: Stage III plus neurostimulation ([@CIT0107]). Resistant BD-I or BD-II depression was defined in a stepped way as failure to reach remission with adequately dosed lithium (0.8 mEq/L) or to other adequate ongoing mood-stabilizing treatment, plus lamotrigine (50--200 mg/d) or with full dose (600 mg/d or more) of quetiapine as monotherapy ([@CIT0218])

To date, the International Society for Bipolar Disorders nomenclature and definitions are the most comprehensive and up to date and utilize both a syndromal (on the basis of DSM criteria) and symptomatic (on the basis of rating scales) approach. These definitions recommend the use of incremental steps for symptom improvement (\<25%, 25--49%, 50--74%, 75--100%) to define response. They propose multiple cut-off points for the definition of remission, with the most stringent being \<6 for Hamilton Depression Rating Scale (HDRS)-17 and Montgomery-Asberg Depression Rating Scale (MADRS) and \<5 for the Young Mania Rating Scale (YMRS) in the case of depression and mania, respectively. These stringent criteria allow for inclusion of subsyndromal states that are very important for failing functional recovery in BD (7--14 in HDRS or MADRS and 8--14 in YMRS). In essence, the definition of subsyndromal states is utilized also for the definition of Treatment Emergent Affective Switch. Non-criterion symptoms that are commonly associated with BD (usually during the depressive phase) such as anxiety, panic attacks, irritability, hopelessness, avoidance, or cognitive dysfunction should not be included in the definitions. These authors defined "recovery" as sustained remission after at least 8 weeks ([@CIT0319]), which is similar to the approach of the AMA ([@CIT0006]). A modified version was proposed several years later ([@CIT0364]).

Another proposal was that treatment-resistant BD should be conceptualized as failure to respond to at least 2 trials of dissimilar medication with presumably adequate doses and durations within a specific phase of bipolar illness (manic, depressive, or mixed) or for "breakthrough"; symptoms. These symptoms should emerge despite previous apparently effective maintenance treatment. There do not refer to patients who are intolerant (In table 4, the grading of treatment options according to safety issues is shown) of a treatment regimen and because of this they refrain from treatment and also to the extent possible, they do not refer to those patients who are not adherent to recommended treatment ([@CIT0237]).

Τhe most recent attempt was to define treatment resistance in terms of failure to reach sustained symptomatic remission for 8 consecutive weeks after 2 different treatment trials, at adequate therapeutic doses, with at least 2 recommended monotherapy treatments or at least 1 monotherapy treatment and another combination treatment. It also introduced the term "multi-treatment-resistant BD" after failure of additional trials with at least 1 trial with an antidepressant, a psychological treatment, and a course of electroconvulsive therapy (ECT) ([@CIT0127]).

Considering the above, the International Society for Bipolar Disorders definition is a good starting point, but the authors suggest that additional considerations are necessary. The key points the therapist needs to consider before suggesting a patient might be treatment-resistant are summarized in [Table 2](#T2){ref-type="table"}. The proposed CINP definitions of response, remission, recovery, and resistance for BD are shown in [Table 3](#T3){ref-type="table"}. According to the authors of the current paper, a key issue is that nonresponse should be considered only after treatment according to the best evidence available. At this time, the options recommended by the CINP guidelines for BD ([@CIT0365], [@CIT0368], [@CIT0369], [@CIT0370]) and the CANMAT Guidelines ([@CIT0353]) provide the most up-to-date and comprehensive overview of treatment options.

###### 

The CINP definitions of response, remission, recovery, and resistance for BD

               Phase                      Scale scores                                                                                                                                               Treatment duration according to CINP guidelines
  ------------ -------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------
  Response     Acute mania                \<25%, 25--49%, 50--74%, 75--100% reduction in YMRS or MRS scores No significant increase in MADRS or HDRS scores and MADRS and HDRS scores stay below 6   8--10 weeks
               Acute Bipolar depression   \<25%, 25--49%, 50--74%, 75--100% reduction in MADRS or HDRS scores No significant increase in YMRS or MRS scores and YMRS and MRS scores stay below 5     10--12 weeks
               Maintenance                Significant change in the frequency of episodes                                                                                                            1 year
  Remission    Acute mania                YMRS and MRS scores stay below 5 No significant increase in MADRS or HDRS scores and MADRS and HDRS scores stay below 6                                    8 weeks
               Acute Bipolar depression   MADRS and HDRS scores stay below 6 No significant increase in YMRS or MRS scores and YMRS and MRS scores stay below 5                                      8 weeks
               Maintenance                Very rare new episodes, and MADRS/HDRS scores \<6 and YMRS/MRS scores \<7 between episodes                                                                 2--3 years?
  Recovery     Acute mania                YMRS and MRS scores stay below 5 No significant increase in MADRS or HDRS scores and MADRS and HDRS scores stay below 6                                    8 weeks
               Acute Bipolar depression   MADRS and HDRS scores stay below 6 No significant increase in YMRS or MRS scores and YMRS and MRS scores stay below 5                                      8 weeks
               Maintenance                No new mood episodes and MADRS/HDRS scores \<6 and YMRS/MRS scores \<7 between episodes                                                                    3--5 years
  Resistance   Acute mania                No significant reduction in YMRS or MRS scores, or significant increase in MADRS or HDRS scores or MADRS and HDRS scores exceed 6                          8--10 weeks
               Acute Bipolar depression   No significant reduction in in MADRS or HDRS scores or significant increase in YMRS or MRS scores or YMRS and MRS scores exceed 5                          10--12 weeks
               Maintenance                No change in the frequency of episodes, or MADRS/HDRS scores \>6 or YMRS/MRS scores \>7 between episodes                                                   1 year

Abbreviations: BD, bipolar disorder; HDRS, Hamilton Depression Rating Scale; MADRS, Mondgomery-Asberg Depression Rating Scale; MRS, Mania Rating Scale; YMRS, Young Mania Rating Scale.

Clinical Correlates of Treatment Resistance (n = 19) {#s6}
----------------------------------------------------

A number of studies suggest that some kind of progression occurs over the long-term course of the illness, and this, in turn, contributes to treatment resistance ([@CIT0027]; [@CIT0103]) with an association to number of mood episodes ([@CIT0304]; [@CIT0215]; [@CIT0286]; [@CIT0254]; [@CIT0026]; [@CIT0065]) and hospitalizations ([@CIT0214]). This progression is not uniform ([@CIT0304]; [@CIT0286]).

Clinical characteristics of treatment-resistant patients are the frequent presence of rapid cycling (37%), other forms of cycling (32%), chronic depression (26%), mixed states (6%) ([@CIT0058]), and anxiety ([@CIT0343]; [@CIT0223]; [@CIT0214]). Other features include melancholia, comorbidity with social phobia, current suicidal risk and severe intensity of current depressive episode ([@CIT0194]), cognitive difficulties, and sleep disturbance ([@CIT0145]; [@CIT0343]). However, some studies failed to identify such clinical markers of resistance ([@CIT0340]; [@CIT0007]; [@CIT0273])

Other features that might distinguish between resistant and nonresistant BD include being female, older, older age at illness onset, a higher incidences of family depression, lower likelihood of being gainfully employed, a higher number of lifetime stressors, medical conditions, a different personality and temperament profile, and more regular use of benzodiazepines ([@CIT0223]). It is believed that substance use and unhealthy lifestyle might contribute to treatment resistance, although data are lacking ([@CIT0280]).

It is important that those clinical variables with supposed value in predicting response or resistance to lithium treatment and including the presence of elation, grandiosity, paranoia, irritability, delusions, and hallucinations did not predict treatment response to lithium ([@CIT0197]).

Overall, the data are of low quality and it is unknown whether the clinical picture is useful in predicting treatment response.

Neurobiological Correlates of Treatment Resistance (n = 3) {#s7}
----------------------------------------------------------

Only 3 studies reported on possible neurobiological correlations of treatment resistance and identified family history of affective disorder ([@CIT0058]; [@CIT0223]) and electroencephalographic abnormalities ([@CIT0058]) as risk factors, while neuroinflammation mechanisms seem to promote the progression towards treatment resistance ([@CIT0015])

Treatment of Resistant BD {#s8}
-------------------------

### Resistant Acute Mania (n = 62) {#s9}

#### Double Blind Studies in the Treatment of Resistant Acute Mania (n = 26) {#s10}

Valproate monotherapy (serum levels 50 and 100 mg/L), in 36 lithium-resistant manic patients (including patients who could not tolerate lithium), produced a 54% decrease in scores on the YMRS in the valproate arm vs a 5% decrease in the placebo arm ([@CIT0239])

In 1 underpowered study, 13 BD-I and 15 BD-II patients received 900--4800 mg/d gabapentin, lamotrigine, or placebo in a crossover design for 6 weeks, and at endpoint there was no difference between the 3 arms ([@CIT0104]). In another study, 114 BD-I outpatients resistant to lithium, valproate, or their combination were randomized to adjunctive gabapentin (600--3600 mg/d) or placebo for up to 10 weeks, with placebo performing better ([@CIT0221]).

There are positive data on add-on phenytoin in patients resistant to haloperidol treatment ([@CIT0198]) and of add-on 600--1200 mg/d carbamazepine or oxcarbazepine in patients resistant to lithium ([@CIT0138]). The second study was of poor quality. A study adding lovastatin to lithium was negative ([@CIT0112]).

In patients resistant to lithium, valproate, or carbamazepine, it is beneficial to add olanzapine, quetiapine, aripiprazole, or asenapine ([@CIT0314]; [@CIT0263]; [@CIT0351]; [@CIT0337]; [@CIT0306]) but not ziprasidone, topiramate, or paliperidone ([@CIT0260]; [@CIT0031]; [@CIT0267], [@CIT0268]). For patients resistant to both lithium and carbamazepine monotherapy, their combination was reported to be beneficial (at dosages corresponding to lithium levels 0.7--1.2 mmol/L and up to 1600 mg/d of carbamazepine) ([@CIT0152]).

One study provided inconclusive data for risperidone ([@CIT0349]) as the results were likely confounded by the effects of carbamazepine on serum levels of risperidone.

There was only 1 sham-controlled trial of ECT as adjunctive treatment to chlorpromazine (600 mg/d) in 30 acutely manic patients and supported the efficacy of ECT with a faster rate of improvement ([@CIT0292]).

One placebo-controlled 4-week random controlled trial in 180 acutely manic patients supported the efficacy and safety of allopurinol (600 mg/d) and dipyridamole (200 mg/d) as adjunctive to lithium ([@CIT0172]). However, a previous study was negative in patients resistant to lithium, valproic acid, carbamazepine, or atypical antipsychotic medications ([@CIT0078]). Findings for valproate are inconclusive ([@CIT0078]; [@CIT0137]).

Folic acid was reported useful as an adjunct to valproate; however, the study is problematic concerning its methods of analysis and the reporting of results ([@CIT0022]). Valnoctamide (the valproic acid precursor) plus risperidone combination was more effective than risperidone plus placebo ([@CIT0030]), while a pilot 8-week study in 21 acutely manic outpatients on the usefulness of adjunctive ramelteon states failed ([@CIT0186]) and another 2 on donepezil were negative ([@CIT0075]; [@CIT0049]).

#### Open Label Studies in the Treatment of Resistant Acute Mania (n = 23) {#s11}

Treating resistant manic patients with olanzapine 5--40 mg/d monotherapy resulted in remission in three-quarters of patients ([@CIT0184]; [@CIT0048]), and several small studies support the efficacy of up to 550 mg/d clozapine with three-quarters of the patients responding after prolonged treatment ([@CIT0148]; [@CIT0041]; [@CIT0053]; [@CIT0122]). The combination of aripiprazole with clozapine in BD patients that failed to respond to other atypical antipsychotics returned a positive result in psychotic manic patients ([@CIT0023]). Results concerning risperidone are equivocal ([@CIT0269]; [@CIT0331])

Adding gabapentin or pregabalin (600--3600 mg/d) resulted in response in three-quarters of resistant manic patients ([@CIT0183]; [@CIT0003]; [@CIT0283]). Only one-quarter of rapid cycling patients responded ([@CIT0003]). Adding 100--300 mg/d topiramate resulted in a response rate of almost 60% ([@CIT0050]; [@CIT0338]) but titrating up to 1300 mg/d did not increase the response ([@CIT0043]). Adding leviracetam (500--1000 mg/d) produced response or remission in one-half of patients ([@CIT0244]); data concerning verapamil (up to 240 mg/d) were negative ([@CIT0014]) while for nifedipine 120 mg/d were unimpressive ([@CIT0068]). Some positive findings exist for diltiazem ([@CIT0293]). Adding l-thyroxine to lithium or carbamazepine resulted in a 50% response rate ([@CIT0021]).

Three-quarters of resistant manic patients respond to ECT ([@CIT0233]) with equal efficacy for unilateral vs bilateral ECT ([@CIT0203]), and bifrontal ECT was as efficacious as bitemporal ECT and better tolerated ([@CIT0013]; [@CIT0128]).

#### Meta-Analytic and Review Studies in the Treatment of Resistant Acute Mania (n = 13) {#s12}

Meta-analytic studies also suggest that combination treatment is superior to monotherapy at the cost of more frequent adverse events; however, these meta-analyses do not distinguish between add-on studies (which utilize patients resistant to monotherapy) and combination studies (which utilize general patient populations) ([@CIT0284]; [@CIT0295]; [@CIT0308]; [@CIT0216]). Due to the insufficient evidence base, earlier reviews provide only vague conclusions (Gitlin, [@CIT0115], [@CIT0114]; [@CIT0140]). Overall, there is a striking paucity of research concerning resistant cases, and existing studies are small and insufficiently controlled and findings remain preliminary. ECT is generally considered as an option for resistant patients. In acute manic patients who are partial responders to lithium/valproate/carbamazepine, adding an antipsychotic is a reasonable choice. Encouraging results have been reported by adding aripiprazole, clozapine, and pregabalin in resistant mania ([@CIT0133]). The analysis of the data for the cholinesterase inhibitors galantamine and donepezil as well as the glutamate receptor antagonist memantine was negative ([@CIT0327]). One meta-analysis of combination studies confirmed the higher rate of adverse events compared with monotherapy ([@CIT0108]). One review of open studies supported the usefulness of clozapine ([@CIT0160]).

There are a few randomized controlled trials of ECT in mania, and they consistently report clinically meaningful efficacy, with a majority of pharmacotherapy-resistant patients responding to ECT. Evidence for the use of other brain stimulation therapies in treating bipolar mood states is preliminary and limited ([@CIT0166]; [@CIT0328]).

#### Conclusion Concerning the Treatment of Resistant Acute Mania {#s13}

Controlled data suggest that in patients resistant (principally) to lithium, valproate, or carbamazepine, it is beneficial to add aripiprazole, asenapine, folic acid, quetiapine, or valnoctamide. The next choice should be adding haloperidol, olanzapine, or phenytoin on lithium, valproate, or carbamazepine. The data are inconclusive concerning allopurinol, carbamazepine, clozapine, ECT, leviracetam, l-thyroxine, oxcarbazepine, and pregabalin.

According to controlled data, the agents not recommended include donepezil, gabapentin, lamotrigine, lovastatin, paliperidone, ramelteon, risperidone, topiramate, and ziprasidone, while additionally, on the basis of open data, nifedipine and verapamil are also not recommended ([Table 5](#T5){ref-type="table"}; [Figure 2](#F2){ref-type="fig"}).

###### 

Grading of treatment options according to safety issues following system shown in [Table 1](#T1){ref-type="table"}

  Agent/modality          Grade   Comments
  ----------------------- ------- --------------------------------------------------------------------------------------------------------------------------------------------------
  Agomelatine             2       Elevation of liver enzymes
  Allopurinol             2       Swelling of mouth and lips, severe skin rashes, infections, eye irritation, hepatitis, appetite and weight loss, and painful or bloody urination
  Amitriptyline           2       Many adverse effects, some risk for cardiovascular events
  Aripiprazole            1       
  Armodafinil/modafinil   2       Stimulant, risk for abuse
  Asenapine               1       
  Bupropion               1       
  Carbamazepine           2       Hepatic enzymes induction, many adverse effects
  Cariprazine             1       
  Celecoxib               1       
  Choline                         Food supplement
  Chromium                        Food supplement
  Clozapine               3       Potentially lethal agranulocytosis, metabolic syndrome
  DBS                     1       
  Diltiazem               1       
  Donepezil               1       
  ECT                     2       Not preferred by patients, mild cognitive problems
  Folic acid                      Food supplement
  Gabapentin              1       
  Galantamine                     
  Haloperidol             2       Extra-pyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, switch risk
  Imipramine              2       Cardiac side effects, many adverse effects, switch risk
  Inositol                        
  Ketamine                3       Transient dissociation and elevation of blood pressure
  Lamotrigine             2       Good overall tolerability but potentially lethal skin reaction that can be avoided by slow titration
  Levetiracetam           3       Induction of suicidality
  Light therapy                   
  Lisdexamfetamine        3       High risk for abuse and dependence
  Lithium                 2       Many adverse effects, weight gain, toxicity
  Lovastatin                      
  L-sulpiride             1       
  l-thyroxine             2       Mild cardiovascular, skin and bone adverse effects
  Lurasidone              1       
  Magnesium                       Food supplement
  Memantine               1       
  Modafinil               2       Stimulant, risk for abuse
  n-3 fatty acids                 Food supplement
  N-acetyl cysteine       1       
  Nimodipine              1       
  Olanzapine              2       Metabolic syndrome
  Omega 3 fatty acids     1       
  Oxcarbazepine           1       
  Paliperidone            1       
  Paroxetine              1       Weight gain
  Phenytoin               2       Many adverse effects
  Pioglitazone            2       Not recommended in patients with diabetes mellitus type I and in liver disease Absolute contraindication in heart failure patients
  Pramipexole             2       Adverse effects include the induction of compulsive behaviors and psychotic symptoms
  Pregabaline             2       Risk of abuse, weight gain
  Pregnenolone            2       Not well studied
  Primidone                       
  Quetiapine              1       Weight gain
  Ramelteon               1       
  Risperidone/RLAI        1       Increased prolactin, weight gain
  S-adenosyl-L-methione   2       Some adverse effects; long-term effects unknown
  Sleep deprivation       1       
  TMS                     1       
  Topiramate              3       Induction of depression and suicidality
  Tranylcypromine         2       Many adverse effects
  Tryptophan                      Food supplement
  Valnoctamide            1       
  Valproate               1       Cautious use in women of childbearing age
  Venlafaxine             2       Switch risk
  Verapamil               1       
  Ziprasidone             2       QTc prolongation, patient ECG recommended when used in combination

Abbreviations: DBS, deep brain stimulation; ECG, electrocardiogram; ECT, electroconvulsive therapy; EPS, extrapyramidal signs; RLAI, risperidon long acting injection; TMS, transcranial magnetic stimulation.

###### 

Levels of recommendation concerning adjunctive treatment for resistant acute mania and recommended dosages for medication options

  Treatment modality to add   Grading        
  --------------------------- --------- ---- -----------------------------------
  Aripiprazole                2         1    Up to 30 mg/d
  Asenapine                   2         1    Up to 20 mg/d
  Quetiapine                  1         1    Up to 800 mg/d
  Valnoctamide                2         1    1200 mg/d
  Haloperidol                 2         2    Up to 12 mg/d
  Olanzapine                  2         2    Up to 40 mg/d
  Phenytoin                   3         3    400 mg/d
  Allopurinol                 4         4    600 mg/d
  Carbamazepine               4         4    Up to 1200 mg/d
  Clozapine                   4         4    Up to 550 mg/d
  ECT                         4         4    --
  Folic acid                  4         4    3 mg/d
  Leviracetam                 4         4    2000--3000 mg/d
  l-Thyroxine                 4         4    Until FT4 higher than upper limit
  Oxcarbazepine               4         4    Up to 1200 mg/d
  Pregabaline                 4         4    75--150 mg/d
  Donepezil                   NR        NR   
  Gabapentin                  NR        NR   
  Lamotrigine                 NR        NR   
  Lovastatin                  NR        NR   
  Nifedipine                  NR        NR   
  Paliperidone                NR        NR   
  Ramelteon                   NR        NR   
  Risperidone                 NR        NR   
  Topiramate                  NR        NR   
  Verapamil                   NR        NR   
  Ziprasidone                 NR        NR   

Abbreviations: ECT, electroconvulsive therapy; FT4, free-T4; NR, not recommended.
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### Mixed Episodes (n = 7) {#s14}

Adding olanzapine or placebo to divalproex-resistant mixed patients for 6 weeks returned positive results both for the manic as well as for the depressive component ([@CIT0132]).

One open study of adjunct gabapentin (300--2000 mg/d) reported an almost 50% response rate but this concerned exclusively the depressive component ([@CIT0230]).

There were no randomized trials of ECT in mixed episodes ([@CIT0166]). The results of open trials concerning the usefulness of ECT suggest that approximately 40% to two-thirds of patients responded and 30% remitted, and the response concerned both the manic and the depressive components ([@CIT0192], [@CIT0193]; [@CIT0233]). One study concerning repetitive transcranial stimulation (rTMS) reported a lower response rate (around 40%) and response restricted to the depressive component ([@CIT0220]).

### Treatment-Resistant BD (n = 145) {#s15}

#### Double Blind Studies in the Treatment of Resistant Acute BD (n = 69) {#s16}

In bipolar depressed patients who experience depression while under lithium treatment, it is appropriate to add lamotrigine ([@CIT0167], 2010, 2011), the D2 antagonist L-sulpiride ([@CIT0035]), pramipexole ([@CIT0116]), or possibly oxcarbazepine ([@CIT0138]) but not imipramine ([@CIT0208]). The data on adding paroxetine and amitriptyline are equivocal ([@CIT0035]; [@CIT0017]; [@CIT0355]; [@CIT0235]; [@CIT0168]). Imipramine and venlafaxine might pose the patients at an increased risk of switching without a superior benefit compared with other antidepressants ([@CIT0208]; [@CIT0334]); however, 1 study suggests quite the opposite ([@CIT0008]). One study suggested that the addition of lamotrigine to quetiapine treatment improved outcomes, but folic acid seems to nullify the effect of lamotrigine ([@CIT0110]).

In BD patients experiencing depression during treatment with lithium or valproate, ketamine or lurasidone could be added. Lurasidone also improves anxiety ([@CIT0165]) and ketamine improves suicidality. Response to a single ketamine infusion may appear within hours but does not last more than 3 to 4 days ([@CIT0072]; [@CIT0356]; [@CIT0155]; [@CIT0165]; [@CIT0346]). One study reported negative results ([@CIT0346]). Besides reducing suicidality, ketamine has been reported to be efficacious especially against anhedonia ([@CIT0155]) and fatigue ([@CIT0271]). Repeated administration of ketamine studies have not been carried in BD ([@CIT0207]; [@CIT0234]). There is 1 failed study with lurasidone as add-on to lithium or valproate ([@CIT0302], [@CIT0303]).

An underpowered placebo-controlled adjunctive study of aripiprazole to lithium and citalopram was negative ([@CIT0251]).

For a depressed episode during treatment with mood stabilizers, it is not beneficial to add ziprasidone ([@CIT0266]; [@CIT0226]). Topiramate and levetiracetam should be avoided because of a risk of worsening depression and inducing suicidality ([@CIT0372]). Imipramine and venlafaxine increased the risk of switching without superior benefits compared with other antidepressants ([@CIT0265], 2011; [@CIT0245], [@CIT0246]; [@CIT0288]; [@CIT0279]; [@CIT0004]; [@CIT0275]).

The data are negative concerning the addition of memantine on lamotrigine ([@CIT0009]) or valproate (Lee et al., 2014a, 2014b), ketamine on ECT ([@CIT0002]), lisdexamfetamine to treatment as usual (TAU) ([@CIT0187]), and agomelatine to lithium or valproate ([@CIT0352]).

A study in 85 patients with adjunctive modafinil (mean dosage 177 mg/d) was positive without switching to mania or hypomania. Response and remission rates were higher in the modafinil group (44% and 39%) compared with the placebo group (23% and 18%) ([@CIT0105]). However, modafinil could cause subclinical switches ([@CIT0366]). One published study for the treatment of acute BD-I depression with adjunct armodafinil (dosage 150 mg/d; n = 128) to lithium, valproate, or olanzapine was positive ([@CIT0044], [@CIT0045]). However, 2 other studies were negative ([@CIT0217]; [@CIT0147]).

One small study on pioglitazone as add-on to lithium in bipolar patients without diabetes mellitus was positive ([@CIT0358]). A trial of celecoxib (400 mg/d) was negative in the treatment of depressive or mixed episodes ([@CIT0209]). One study with add-on pregnenolone (titrated to 500 mg/d) was negative ([@CIT0038]). While a very small report without an a priori defined primary outcome suggested that adding supraphysiologic doses of levothyroxine (L-T4) to a mood stabilizer improves the outcome ([@CIT0019]), a previous, more complete report on the same placebo-controlled dataset was negative ([@CIT0296]). That study reported positive findings in females but not in males. A small quasi-placebo-controlled study was positive concerning the addition of inositol ([@CIT0051]).

A 24-week trial on the efficacy of N-acetyl cysteine (NAC, 1 g twice daily) adjunctive to usual medication in subsyndromal but treatment-resistant depressive symptoms was positive ([@CIT0025]); however, a more recent study was negative ([@CIT0361], [@CIT0362]). The data on omega-3 fatty acids are conflicting and inconclusive ([@CIT0297]; [@CIT0101], [@CIT0102]; [@CIT0141]; [@CIT0204]). One negative study exists concerning S-adenosyl-L-methione up to 1400 mg/d ([@CIT0205]).

ECT may be more effective than pharmacotherapy for treatment-resistant bipolar depression ([@CIT0285]) but TMS is poorly investigated in bipolar depression ([@CIT0070]). Active deep TMS was superior to sham at end point (*P* = .03) but not at follow-up ([@CIT0309]). One study on transcranial direct current stimulation reported that the cumulative response rates were higher in the active vs sham groups (67.6% vs 30.4%; *P* = .01) but not remission rates (37.4% vs 19.1%; *P* = .18) ([@CIT0272]).

Sleep deprivation and other noninvasive circadian-related interventions could be useful add-on treatments to accelerate and sustain the antidepressant response ([@CIT0345]). A study on bright light therapy in bipolar depression was negative ([@CIT0066]), whereas other controlled studies were positive ([@CIT0294]; [@CIT0354]; [@CIT0360]).

#### Open Label Studies in Treatment of Resistant Acute Bipolar Depression (n = 32) {#s17}

One study reported a 31% response rate with add-on levetiracetam titrated to a target dose of 2000 mg/d ([@CIT0244]). Another study supported the adjunctive therapy with diltiazem ([@CIT0293]).

Adding bupropion to ongoing treatment after 4 weeks yielded a 60% response ([@CIT0076]) while adding tranylcypromine in imipramine-resistant patients resulted in a 75% response ([@CIT0311]).

Resistant depressive patients from the STEP-BD trial were randomly assigned to open-label adjunctive treatment with lamotrigine, inositol, or risperidone for up to 16 weeks without any significant between-group differences. However, the recovery rate with lamotrigine was 23.8% vs 17.4% with inositol and 4.6% with risperidone ([@CIT0211]). Another STEP-BD subgroup received adjunctive aripiprazole, but the response rate was as low as 27% ([@CIT0146]).

Adjunctive gabapentin for 12 weeks (mean dose 1725 mg/d) resulted in a 55% response ([@CIT0341]) and for 8 weeks with mean dosage 1270 ± 561 mg in a 42% response rate ([@CIT0231]). A third very small trial (n = 5) reported that all patients responded to adjunctive gabapentin ([@CIT0003]).

Adding lamotrigine 75--100 mg/d resulted in an approximately 50--70% response ([@CIT0154]; [@CIT0211]; [@CIT0139]).

Adding levetiracetam up to 3000 mg/d resulted in 31% remission ([@CIT0244]). Approximately 23% of patients from the Stanley Foundation Bipolar Network long-term follow-up study responded after adding 8.7 mg/d of tiagabine ([@CIT0299]) and one-half of patients responded to topiramate ([@CIT0338]). Two-thirds of patients responded to 0.95 mg/d pramipexole ([@CIT0156]).

There were 3 positive papers (2 on the same dataset) on the utilization of a single infusion of ketamine (0.5 mg/kg) over 40 min resulting in a 50% response ([@CIT0261], [@CIT0262]; [@CIT0135]). One small study was positive for omega-3 fatty acids ([@CIT0052]).

More than one-half of patients and two-thirds of those with BD-I are reported to respond to ECT ([@CIT0191], 2010; [@CIT0232], 2017; [@CIT0285]) while one-fourth manifest remission ([@CIT0192]). One study, however, reported similar remission rates with an algorithm-based pharmacological treatment (34.8% vs 30.0%) ([@CIT0285]). Another study with nonconvulsive electrotherapy reported 73% response and 55% remission rates ([@CIT0253]).

Early rTMS studies reported a 60% response rate ([@CIT0070]; [@CIT0344]). One study of sequential bilateral rTMS vs sham treatment was negative with both arms having a 10% response rate ([@CIT0079]), but another with high-frequency repetitive transcranial magnetic stimulation reported 35% response and 30% remission rates ([@CIT0236]).

The results with deep brain stimulation in a very small study were rather poor (\<20% acute response and remission rates) ([@CIT0129]), and similarly a study with deep (H1-coil) transcranial magnetic stimulation (deep TMS) vs sham was superior at week-4 in HDRS but not at follow-up at week-8. There was no difference in response and remission rates ([@CIT0309]). An earlier H1-Coil rTMS study reported that two-thirds of patients responded and one-half of them remitted ([@CIT0125]).

Total sleep deprivation plus light therapy for 1 week resulted in a 44% response in resistant patients ([@CIT0024]).

#### Post-hoc, Review, and Meta-Analytic Studies (n = 48) {#s18}

The problems in the literature concerning the treatment of resistant bipolar depression are described in several reviews and meta-analytical studies. The overall conclusion is that the available hard data are extremely scarce and most of the strategies remain essentially experimental; however, there seem to be some that are potentially efficacious and promising ([@CIT0001]; [@CIT0237]; [@CIT0291]; [@CIT0133]). In addition, combination studies confirmed the higher rate of adverse events compared with monotherapy ([@CIT0108]).

Existing papers suggest minimal effects of lamotrigine, risperidone, inositol ([@CIT0222]), or lurasidone ([@CIT0274]) and that the addition of an antidepressant does not increase efficacy ([@CIT0222]; [@CIT0324]). The combination with best data in resistant acute bipolar depression is lithium plus lamotrigine ([@CIT0371]). Antidepressant reviews provide conflicting conclusions ([@CIT0113]; [@CIT0290]; [@CIT0326]; [@CIT0359]); 1 meta-analysis was negative regarding the usefulness of galantamine, donepezil, and memantine ([@CIT0327]) while another concluded that second-generation antidepressants produced a significant but small score change but had no effect in response and remission rates. There was also no increased risk of treatment-emergent mania or hypomania during the acute phase while there was some risk in the long term ([@CIT0189]).

Some studies support the efficacy of stimulants, especially modafinil and armodafinil ([@CIT0062]), ketamine ([@CIT0062]; [@CIT0081]; [@CIT0188]), and antiinflammatory agents ([@CIT0259]). A meta-analytic study supported the efficacy of dopaminergic drugs ([@CIT0307]). The review of pramipexole data suggested that two-thirds of patients respond ([@CIT0069]; [@CIT0321]).

The meta-analysis of ketamine studies supported its efficacy but also suggested the data are conflicting as to whether the therapeutic effect extends beyond day 4 and up to day 7 ([@CIT0291]; [@CIT0040]; [@CIT0080]; [@CIT0081]; [@CIT0321]; [@CIT0064]; [@CIT0157]; [@CIT0188]; [@CIT0210]; [@CIT0224]; [@CIT0257]; [@CIT0034]; [@CIT0149]; [@CIT0271]; [@CIT0347]; [@CIT0153]).

One meta-analysis was positive concerning the usefulness of light therapy ([@CIT0322]).

Reviews and meta-analyses are positive concerning omega-fatty acids, but they do not include all trials ([@CIT0276]; [@CIT0305]; [@CIT0123]; [@CIT0055]). Another meta-analysis was negative for adjunctive inositol ([@CIT0202]) and another one supported the usefulness of clozapine ([@CIT0160]).

There are no studies with adequate methodology on ECT ([@CIT0166]; [@CIT0328]). One meta-analysis compared the efficacy of ECT in unipolar vs bipolar depression and identified 6 relevant studies. It reported a similar rate of response in both disorders (50.9% vs 53.2%) ([@CIT0073]).

A meta-analysis of rTMS in bipolar depression, although based overall on a smaller number of participants, supported efficacy ([@CIT0190]).

One post-hoc study pooled the data from transcranial direct current stimulation (transcranial direct current stimulation) trials and reported significant positive results ([@CIT0074]) while a review suggested that Vagus nerve stimulation is promising for bipolar depression ([@CIT0056]). Another review focused on surgical interventions but without any conclusion ([@CIT0162]).

#### Conclusion Concerning the Treatment of Resistant Acute Bipolar Depression {#s19}

Controlled data suggest that in resistant bipolar depressive patients, it is beneficial to use lithium plus lamotrigine or adding lamotrigine, modafinil, or pramipexole. Ketamine is also another option but carries the risk of transient dissociation and increased blood pressure. The data are inconclusive concerning L-sulpiride, amitriptyline, bupropion, clozapine, diltiazem, ECT, gabapentin, l-thyroxine, lurasidone, NAC, omega-3 fatty acids, oxcarbazepine, paroxetine, pramipexole, sleep deprivation, TMS, tranylcypromine, and venlafaxine.

According to either controlled or open data, the interventions not recommended include agomelatine, aripiprazole, celecoxib, deep brain stimulation, galantamine, imipramine, inositol, leviracetam, lisdexamfetamine, memantine, pregnenolone, S-adenosyl-L-methione, topiramate, and ziprasidone ([Table 6](#T6){ref-type="table"}; [Figure 3](#F3){ref-type="fig"}).

###### 

Levels of recommendation concerning adjunctive treatment for resistant acute bipolar depression and recommended dosages for medication options

  Treatment modality to add   Grading        
  --------------------------- --------- ---- --------------------------------
  Lamotrigine (on lithium)    1         2    Up to 200 mg/d
  Light therapy               1         1    
  ECT                         2         2    
  Modafinil                   2         2    Up to 200 mg/d
  Pramipexole                 2         2    Up to 2.5 mg/d
  TMS                         2         2    
  Pioglitazone                3         3    30 mg/d
  Amitriptyline               4         4    Up to 150 mg/d
  Bupropion                   4         4    Up to 375 mg/d
  Clozapine                   4         4    Up to 600 mg/d
  Diltiazem                   4         4    Up to 240 mg/d
  Gabapentin                  4         4    600--2400 mg/d
  L-sulpiride                 4         4    50--75 mg/d
  N-acetyl cysteine           4         4    2000 mg/d
  Ketamine                    1         4    Intravenous infusion 0.5 mg/kg
  l-Thyroxine                 4         4    300 mcg/d
  Lurasidone                  4         4    Up to 120 mg/d
  Omega-3 fatty acids         4         4    Various
  Oxcarbazepine               4         4    Up to 1200 mg/d
  Paroxetine                  4         4    Up to 40 mg/d
  Pramipexole                 4         4    3 mg/d
  Sleep deprivation           4         4    --
  Tranylcypromine             4         4    30--60 mg/d
  Venlafaxine                 4         4    75--225 mg/d
  Agomelatine                 NR        NR   
  Aripiprazole                NR        NR   
  Celecoxib                   NR        NR   
  DBS                         NR        NR   
  Galantamine                 NR        NR   
  Imipramine                  NR        NR   
  Inositol                    NR        NR   
  Leviracetam                 NR        NR   
  Lisdexamfetamine            NR        NR   
  Memantine                   NR        NR   
  Pregnenolone                NR        NR   
  S-adenosyl-L-methione       NR        NR   
  Topiramate                  NR        NR   
  Ziprasidone                 NR        NR   

Abbreviations: DBS, deep brain stimulation; ECT, electroconvulsive therapy; NR, not recommended; TMS, transcranial magnetic stimulation.

![Algorithm for the treatment of resistant acute bipolar depression.](pyz064f0003){#F3}

### BD Resistant to Maintenance Treatment (n = 49) {#s20}

#### Double-Blind Studies in Maintenance Treatment of Resistant BD (n = 24) {#s21}

A small study supported the adding of phenytoin to TAU ([@CIT0199]) as did another small one for gabapentin (but not on top of antipsychotics) ([@CIT0333]). One study suggested a beneficial effect of clozapine on a small subsample of nonpsychotic BD ([@CIT0298]). Data are equivocal for the addition of lamotrigine to lithium ([@CIT0169]) and negative for adjunctive pramipexole to TAU in stabilized BD patients with the aim to improve neurocognition ([@CIT0039]). Two studies suggest that Risperidone Long Acting Injectable (RLAI) on TAU significantly prolongs the time to relapse ([@CIT0171]; [@CIT0252]), as did adding aripiprazole ([@CIT0180]) or ziprasidone ([@CIT0057]) to lithium or valproate. Adding aripiprazole to lamotrigine did not improve long-term outcome ([@CIT0047]). Patients who responded to treatment with lithium, valproate, or carbamazepine plus antidepressants were more likely to maintain response with continuation of the combined treatment; however, those patients who manifested only a partial acute response were unlikely to further improve when the same treatment was continued ([@CIT0004]). Adjunctive asenapine to lithium or valproate was well tolerated for up to 52 weeks, but no efficacy data were reported from that trial due to lack of statistical power ([@CIT0306]).

One trial in 75 BD patients reported that NAC treatment caused a significant improvement on the MADRS score compared with placebo (*P* = .002) during maintenance. There was no effect of NAC on time to a mood episode and no significant between-group differences in adverse events ([@CIT0025]). Another study in 14 BD-II patients from the previous study reported a superiority of the NAC group vs placebo in terms of remission (*P* = .031) ([@CIT0375]). Data were conflicting concerning ramelteon ([@CIT0213]; [@CIT0176]) and negative results for memantine in patients on valproate treatment ([@CIT0374]).

There are some studies suggesting that there is a role for various nutritional supplements such as n-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid), chromium, choline, magnesium, and tryptophan alone or in combination with pharmacotherapies for the treatment of BD, but the data are of low quality ([@CIT0305]).

#### Open-Label Studies in Maintenance Treatment of Resistant BD (n = 22) {#s22}

Open studies support the usefulness of adding clozapine ([@CIT0298]; Ciapparelli et al., 2000, [@CIT0054]), gabapentin ([@CIT0281]), lamotrigine ([@CIT0042]), levetiacetam ([@CIT0244]), RLAI ([@CIT0350]), and the anticonvulsant primidone ([@CIT0282]) with approximately 30--40% of patients responding, while a higher than 40% response rate was reported for olanzapine ([@CIT0184]; [@CIT0336]), higher than 50% with L-thyroxine T(4) ([@CIT0018]), and higher than 70% for the N-methyl-D-aspartate antagonist memantine ([@CIT0151]).

One-third of participants responded well to the combination of lithium plus valproate ([@CIT0071]), but the BALANCE study neither supported nor refuted the superiority of the combination of lithium plus valproate over monotherapy ([@CIT0109]; [@CIT0256]; [@CIT0134]). Results were somewhat positive also for the combination of carbamazepine plus nimodipine, but negative for adding the calcium channel blocker verapamil ([@CIT0228]). For overweight patients, adding topiramate ([@CIT0185]; [@CIT0170]; [@CIT0106])or zonisamide ([@CIT0342]) could be an option. However, mood destabilization was observed in another study with the addition of zonisamide.

Using maintenance ECT for more than 18 months, with a treatment at approximately monthly intervals, resulted in an up to 80% response rate ([@CIT0325]).

#### Post-hoc, Review, and Meta-Analytic Studies (n = 10) {#s23}

Meta-analyses support the efficacy of antidepressants added to mood stabilizers in the long-term treatment of bipolar patients without increasing risk of new manic/hypomanic episodes ([@CIT0163]). Ziprasidone plus lithium or valproate treatment showed modest to moderate remission rates at week 24 based on 4 different remission criteria in terms of symptomatic and sustained remission ([@CIT0219]).

The addition of an atypical antipsychotic-antimanic agent in some BD patients might help to reduce suicidal ideation ([@CIT0131]). Efficacy of NAC was also supported by 2 post-hoc analyses ([@CIT0376], [@CIT0175]), which, however did not include more recent negative data. Two other studies supported the usefulness of RLAI ([@CIT0033]) for the maintenance treatment of BD-I disorder in adults as an adjunct to lithium or valproate. One paper supported the usefulness of the dopamine agonist pramipexole ([@CIT0069]). Overall, the review papers support the usefulness of ECT ([@CIT0323]; [@CIT0371]), the combination of antiepileptics with antipsychotics ([@CIT0371]), and clozapine ([@CIT0160]) for the maintenance treatment of resistant patients.

#### Conclusion Concerning Treatment for Resistant Patients During Maintenance Phase {#s24}

Controlled data suggest that in resistant patients (principally to lithium, valproate, or carbamazepine), it is beneficial to add antidepressants, RLAI, aripiprazole, or ziprasidone to the ongoing treatment. The next choice should be adding gabapentin or phenytoin. The data are inconclusive concerning clozapine, ECT, leviracetam, lithium plus lamotrigine or valproate, L-thyroxine, the calcium blocker nimodipine, olanzapine, primidone, ramelteon, and the food supplements choline, chromium, magnesium, n-3 fatty acids, and tryptophan.

According to either controlled or open data, the nonrecommended agents include memantine, NAC, pramipexole, and verapamil. Aripiprazole plus lamotrigine was also not effective ([Table 7](#T7){ref-type="table"}; [Figure 4](#F4){ref-type="fig"}).

###### 

Levels of recommendation concerning adjunctive treatment for resistant patients during maintenance phase and recommended dosages for medication options

  Treatment modality to add               Grading        
  --------------------------------------- --------- ---- ---------------------------
  RLAI                                    1         1    Up to 100 mg/mo
  Aripiprazole                            2         2    Up to 30 mg/d
  Ziprasidone                             2         2    Up to 160 mg/d
  Gabapentin                              3         3    Up to \>2500 mg/d
  Phenytoin                               3         3    380 mg/d
  Choline                                 4         4    --
  Chromium                                4         4    --
  Clozapine                               4         4    Up to 600 mg/d
  ECT                                     4         4    --
  Leviracetam                             4         4    Up to 3000 mg/d
  Lithium plus lamotrigine or valproate   4         4    Usual recommended dosages
  L-Thyroxine                             4         4    500 μg/d
  Magnesium                               4         4    --
  n-3 fatty acids                         4         4    --
  Nimodipine                              4         4    Up to 360 mg/d
  Olanzapine                              4         4    Up to 30 mg/d
  Primidone                               4         4    Up to 250 mg/d
  Ramelteon                               4         4    8 mg/d
  Tryptophan                              4         4    
  Aripiprazole plus lamotrigine           NR        NR   
  Memantine                               NR        NR   
  N-acetyl cysteine                       NR        NR   
  Pramipexole                             NR        NR   
  Verapamil                               NR        NR   

Abbreviations: DBS, deep brain stimulation; ECT, electroconvulsive therapy; NR, not recommended; TMS, transcranial magnetic stimulation.
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It is important to note that the scarcity of the data does not permit a differential choice between agents and treatment options to prevent the relapse into a manic or depressive episode preferentially.

### Resistant Rapid Cycling Cases (n = 10) {#s25}

The data on resistant patients with rapid cycling course are very few. Overall, they suggest that the combination of lithium plus divalproex for up to 16 weeks leads to only 14% stabilization with no additional value of adjunct lamotrigine ([@CIT0143]). One small trial of clorgyline 2.5--10.0 mg/d, alone or in combination with lithium carbonate, was positive ([@CIT0250]), while clozapine was found to be less efficacious in resistant rapid cycling patients ([@CIT0301]; [@CIT0160]). On the contrary, lamotrigine as an add-on therapy exerted a similar effect in rapid and non-rapid cycling patients ([@CIT0037]). A small cross-over, double blind study was positive for adjunctive nimodipine ([@CIT0227]).

Adding mexiletine 200--1200 mg/d led to 46% remission and 15% partial response ([@CIT0278]) while levothyroxine improved only depressive symptoms ([@CIT0021]). Vagus nerve stimulation was associated with a 38.1% mean improvement in overall illness over a 12-month study period ([@CIT0179]). Adding chromium resulted in an acute response in one-third of patients, but only regarding depression. The high drop-out rate made it impossible to test for maintenance efficacy ([@CIT0005]).

### Lithium Discontinuation-Induced Treatment Resistance (n = 10) {#s26}

Treatment resistance possibly induced by lithium discontinuation was suggested for the first time by Post et al following a systematic life-chart methodology in the study of 4 patients with BD in whom long periods (6--15 years) of effective lithium prophylaxis were followed by relapses on lithium discontinuation. Once the drug was reinstituted, it was no longer effective ([@CIT0248]). However, the reason for discontinuation in these 4 cases was not reported, and the discussion of these cases clearly leaves room for a progression of the illness rather than a specific lithium-related cause as the most probable explanation.

Case reports and selected reviews support this ([@CIT0249]; [@CIT0016]; [@CIT0206]; [@CIT0150]; [@CIT0177]; [@CIT0320]; [@CIT0247]; [@CIT0243]) but the arguments are scientifically weak.

The only existing systematic review and meta-analysis of the literature identified the existence of 212 patient data relevant to this question and the meta-analysis returned negative results, suggesting there is no convincing evidence that lithium is less effective when treatment is discontinued and restarted compared with uninterrupted treatment ([@CIT0339]).

### Psychological Treatments (n = 21) {#s27}

There are some but overall limited data of problematic quality concerning the usefulness of specific adjunctive psychotherapies ([@CIT0255]; [@CIT0200]).

Although the overall data for the long-term efficacy of cognitive-behavioral therapy (CBT) either as monotherapy or as add on to TAU are negative concerning relapse prevention, there are some positive results for the acute depressive phase in BD ([@CIT0012]; [@CIT0286]; [@CIT0357]; [@CIT0063]; [@CIT0117]; [@CIT0196]; [@CIT0120]). The effectiveness of psychotherapy for resistant patients was reported to increase with time, and this improvement was not significant until 12 months of follow-up ([@CIT0118], [@CIT0119]; [@CIT0136]). A post-hoc analysis suggested that CBT could be more effective than TAU in patients with less than 12 previous episodes but less effective in those with more episodes ([@CIT0286]). In BD patients with insomnia, CBT for insomnia was superior to psychoeducation concerning manic relapses ([@CIT0126]).

The data on adjunctive psychoeducation suggest that compared with TAU or nonspecific intervention, it prevents relapse to both poles if administered to patients in clinical remission ([@CIT0229]; [@CIT0059]; [@CIT0060]; [@CIT0164]; [@CIT0067]), but it has no effect on biological rhythms ([@CIT0046]). Again, a post-hoc analysis suggested that patients with more than 7 episodes did not show significant improvement with group psychoeducation for time to recurrence, and those with more than 14 episodes did not benefit from the treatment in terms of time spent ill ([@CIT0061]). A systematic review confirmed the above ([@CIT0036]).

There are no data to support the usefulness of interpersonal and social rhythm therapy, family focus treatment, intensive psychosocial intervention, cognitive remediation and functional remediation, mindfulness-based interventions (MBCT), or internet-based interventions in the treatment of resistant BD patients.

Overall, there are limited data to suggest that any kind of psychotherapy is useful in resistant BD patients; some data suggest that it could be useful in resistant patients at the early stages of the disorder.

Algorithm for Treatment of Resistant BD {#s28}
=======================================

A visual representation of the recommended steps in the treatment of resistant cases during each phase is shown in [Figures 2--4](#F2 F3 F4){ref-type="fig"}. As already mentioned, this specific algorithm is based on the materials collected to develop a general algorithm for BD by the CINP (Fountoulakis et al., 2017a, 2017b, 2017c, 2017d).

The authors decided that although mixed episodes are not included in DSM-5, it would be important to include a guidance option for them since some relevant data do exist. Also, they decided to include a recommendation for adding CBT and/or psychoeducation at a level higher than the evidence suggests, because, if available, they could be added without problems to existing pharmacotherapy. However, the recommendation is that this addition should not interfere with the application of the algorithm itself, that is, the first step of the algorithm concerning pharmacotherapy should always be initialized and pseudo-resistance should have been ruled out ([@CIT0280]).

Discussion {#s29}
==========

The current guidelines are the first to our knowledge developed specifically for the treatment of resistant bipolar patients, and they also include an operationalized definition of treatment resistance.

The key issue is the definition of "response," since this is a prerequisite for the definition of "resistant." There are several papers defining response, remission, and resistance in mental disorders, and it seems that all the definitions are characterized by a rather narrow and vague approach. With BD, these definitions face a particular problem. They perform well with disorders with a predominantly linear course, characterized by exacerbations and remissions and with a single major factor or constellation of symptoms (e.g., unipolar melancholic depression). They also perform relatively well with complex disorders like schizophrenia that, in spite of the large variability of the clinical picture (to the extent it is possible 2 patients with schizophrenia not sharing a single symptom), their treatment is more or less unimodal (antipsychotics) and the course of the disease is monotonous. In BD, however, the course is characterized by episodes of distinct clusters of symptoms while the resulting accumulated stress has a profound adverse effect on neurocognition and general functioning with the neurobiology of the patient to change under the pressure of what is called "allostatic load," leading eventually to treatment resistance, disability, high comorbidity, and preterm mortality ([@CIT0335]).

When it comes to BD, things are quite different from other mental disorders. The reliability and validity of usual approaches are questionable because both the clinical picture and the treatment are complex and interrelated. Also, the course is not monotonous but, on the contrary, it manifests with unpredictable switches with a complex and unique relationship between clinical symptoms and impairment. Another issue is the problematic interplay of the clinical picture with psychometric scale scores when the longitudinal course of the disorder is complex, as in the case of BD. For example, the use of the MADRS scale to assess response to treatment with a tricyclic antidepressant could lead to erroneous conclusions in case this depressive BD patient becomes mixed or rapid cycling emerges. The MADRS will probably classify him as being a "responder," but whether this is true is a matter of debate. Accepting simplistic approaches cannot serve as a real solution.

The current study developed a definition of treatment resistance in BD and an algorithm for its treatment. These were based on a thorough and deep search of the literature. During the last couple of decades, our knowledge concerning the treatment of BD has changed radically ([@CIT0121]; [@CIT0329]), and a rather narrow therapeutic effect for most agents is accepted, so narrow that the very existence of the term "mood stabilizer" is under question. Further, the collapse of the "class effect" approach to BD treatment ([@CIT0258]) raises important questions as to which patients are truly resistant and which were simply treated in a suboptimal way.

The review of the literature suggested that there are some evidence-based options for the treatment of resistant acute mania but much fewer for the treatment of resistant depression, mixed states, and rapid cycling cases. Thus, the relative shortage of hard data ([@CIT0237]) leaves the clinician in many cases with the heavy burden to decide on the basis of clinical experience and wisdom. The current treatment guidelines on one hand rely on hard data; however, they provide a limited number of options for the treatment of a variety of cases, and without the ability to tailor treatment to the clinical picture and the specific needs of the individual patient. Future specific and targeted research is essential and necessary to test possible treatment approaches for resistant patients of all kinds.

Most of the problems concerning the interplay of clinical features with definitions of response and resistance, especially for the maintenance phase, have been discussed elsewhere ([@CIT0111]; [@CIT0363]; [@CIT0330]; Fountoulakis et al., 2017b, 2017c, 2017d). Clinical wisdom is also of high importance in the planning of long-term treatment of BD patients. In this frame, the concept of "predominant polarity" and the "polarity index" of a given agent are of great importance since it guides the clinician to tailor treatment to the specific needs of the specific patient ([@CIT0212]; [@CIT0240], [@CIT0241], [@CIT0242]; [@CIT0287]).

Better knowledge of the underlying neurobiological substrate of treatment resistance in BD would be important, since the failure of physiological compensatory mechanisms over time, accompanied by neuroprogression and cross-sensitization of episode recurrence, trauma exposure, and substance use could constitute modifiable factors both in the prevention but also in the treatment of such cases ([@CIT0065]). So far, however, our knowledge does not permit a reliable prediction or assessment of resistant cases since no neurobiological or clinical variables have proven reliable ([@CIT0119]). However, the observation that psychoeducation is preferentially efficacious in patients with less than 7 episodes, while it has no effect in those with more than 14 episodes, provides us with a first clue of the stages and the timetable of the development of resistance ([@CIT0061]; [@CIT0036]; [@CIT0181]). On the other hand, while the stage of the progression of the disorder has been proposed as a factor that should be taken into consideration in the planning of treatment especially in resistant cases ([@CIT0225]), in essence this might reflect a cyclical logic with treatment resistance defining the stage and vice versa.
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